Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
DNAH17 antisense RNA 1 (DNAH17-AS1)
- Target
- DNAH17-AS1
- Molecular classification
- Long non-coding RNA (lncRNA), Antisense RNA, Non-coding RNA, RNA Gene
01
Overview
DNAH17 antisense RNA 1 is a long non-coding RNA (lncRNA) gene transcribed from the DNAH17 locus in the human genome. This molecule does not encode a protein but instead regulates gene expression at multiple levels. Mechanistically, DNAH17-AS1 acts as an antisense RNA, binding to microRNAs and other RNA-binding proteins, thereby affecting the stability and translation of target messenger RNAs. DNAH17-AS1 is upregulated in several cancers, such as non-small cell lung cancer and pancreatic carcinoma, where it promotes cell proliferation, migration, invasion, and suppresses apoptosis, functioning as an oncogenic lncRNA via ceRNA (competitive endogenous RNA) mechanisms. Clinically, its expression is associated with tumor progression and patient survival, highlighting its potential as both a biomarker and a therapeutic target. Additionally, it is implicated in male infertility relating to spermatogenic failure by possibly regulating DNAH17 heavy chain protein expression.
- Other names
- DNAH17-AS1DNAH17 antisense RNA 1
02
Mechanism of action
For hypothetical drugs (antisense oligonucleotides): inhibition via RNA degradation, miRNA sponge blocking, or translation inhibition
03
Biological functions
Regulation of gene expressionMicroRNA (miRNA) sponge activity (competing endogenous RNA)Interaction with RNA-binding proteinsModulation of cell proliferation, migration, and survival in cancer cellsPotential regulation of epigenetic states (by analogy with other antisense lncRNAs)
04
Disease associations
Cancer (oncogenesis, metastasis, used as biomarker and possible therapeutic target; in non-small cell lung cancer and pancreatic carcinoma)Male infertility (associated with spermatogenic failure and disorders of spermatogenesis, probably by regulating DNAH17 expression)
05
Safety considerations
Off-target effects due to RNA sequence similarityPotential unintended epigenetic consequencesDelivery challenges for nucleic acid–based therapies
06
Biomarkers
DNAH17-AS1 expression levels can serve as a biomarker for disease prognosis, especially in non-small cell lung cancer (NSCLC) for tumor progression, metastasis, and patient survivalBiomarker for male infertility due to spermatogenic failure
Beyond the preview
Go deeper on DNAH17 antisense RNA 1 (DNAH17-AS1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DNAH17 antisense RNA 1 (DNAH17-AS1).